Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice

Histology and Histopathology

Volumn 26, Issue 2, 2011, Pages 201-211

  Leung, Tung Ming ^a,b   Fung, Man Lung ^b   Liong, Emily C ^b   Lau, Thomas Y H ^c   Nanji, Amin A ^a   Tipoe, George L ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

L arginine; Liver fibrosis; Nitric oxide; Nitric oxide synthases; SMT

Indexed keywords

ACTIN; ARGININE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; DRUG DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NOS2 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; S METHYLISOTHIOPSEUDOURONIUM; S-METHYLISOTHIOPSEUDOURONIUM; THIOUREA DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; DRUG COMBINATION; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; GENE EXPRESSION REGULATION; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER CELL; MALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

ACTINS; ANIMALS; ARGININE; BIOLOGICAL MARKERS; CYCLOOXYGENASE 2; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HEPATOCYTES; ISOTHIURONIUM; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

MUS;

EID: 78651305270     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Akpolat N., Yahsi S., Godekmerdan A., Yalniz M. and Demirbag K. (2005). The value of alpha-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: a histopathological and immunohistochemical study. Histopathology 47, 276-280.
2. Arthur M. J., Friedman S. L., Roll F. J. and Bissell D. M. (1989). Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J. Clin. Invest. 84, 1076-1085.
3. Badid C., Mounier N., Costa A. M. and Desmouliere A. (2000). Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies. Histol. Histopathol. 15, 269-280.
4. Bataller R. and Brenner D. A. (2005). Liver fibrosis. J. Clin. Invest. 115, 209-218.
5. Bedossa P. and Paradis V. (2003). Liver extracellular matrix in health and disease. J. Pathol. 200, 504-515.
6. Benyon R. C. and Arthur M. J. (2001). Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21, 373-384.
7. Bissell D. M. (1998). Hepatic fibrosis as wound repair: a progress report. J. Gastroenterol. 33, 295-302.
8. Callejas N. A., Bosca L., Williams C. S., DuBois R. N. and Martin-Sanz P. (2000). Regulation of cyclooxygenase 2 expression in hepatocytes by CCAAT/enhancer-binding proteins. Gastroenterology 119, 493-501.
9. Carpino G., Morini S., Ginanni C. S., Franchitto A., Merli M., Siciliano M., Gentili F., Oneti Muda A., Berloco P., Rossi M., Attili A. F. and Gaudio E. (2005). Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig. Liver Dis. 37, 349-356.
10. Chan C. C. and Rodger I. W. (1997). Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases. Adv. Exp. Med. Biol. 407, 157-161.
11. Chen J. H., Tipoe G. L., Liong E. C., So H. S. H., Leung K. M., Tom W. M., Fung P. C. W. and Nanji A. A. (2004). Green tea polyphenols prevent toxin-induced hepatoxicity in mice by down-regulating inducible nitric oxide derived pro-oxidants. Am. J. Clin. Nutr. 80, 742-751.
12. Clemens M. G. (1999). Nitric oxide in liver injury. Hepatol. 30, 1-5.
13. Edwards D. R., Murphy G., Reynolds J. J., Whitham S. E., Docherty A. J., Angel P. and Heath J. K. (1987). Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 6, 1899-1904.
14. Friedman S. L. (2008). Liver fibrosis - from bench to bedside. J. Hepatol. 38 (Suppl 1), S38-S53.
15. Geerts A. (2001). History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin. Liver. Dis. 21, 311-335.
16. Grande J. P., Melder D. C. and Zinsmeister A. R. (1997). Modulation of collagen gene expression by cytokines: stimulatory effect of transforming growth factor-beta1, with divergent effects of epidermal growth factor and tumor necrosis factor-alpha on collagen type I and collagen type IV. J. Lab. Clin. Med. 130, 476-486.
17. Guido M., Rugge M., Chemello L., Leandro G., Fattovich G., Giustina G., Cassaro M. and Alberti A. (1996). Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J. Hepatol. 24, 301-307.
18. Hellerbrand C., Stefanovic B., Giordano F., Burchardt E. R. and Brenner D. A. (1999). The role of TGF-beta1 in initiating hepatic stellate cell activation in vivo. J. Hepatol. 30, 77-87.
19. Hon W. M., Lee K. H. and Khoo H. E. (2002). Nitric oxide in liver diseases: friend, foe, or just passerby? Ann. NY Acad. Sci. 962, 275-295.
20. Hu K. Q. (2003). Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukot. Essent. Fatty Acids 69, 329-337.
21. Iredale J. P. (1997). Tissue inhibitors of metalloproteinases in liver fibrosis. Int. J. Biochem. Cell Biol. 29, 43-54.
22. Knittel T., Mehde M., Kobold D., Saile B., Dinter C. and Ramadori G. (1999). Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J. Hepatol. 30, 48-60.
23. Knittel T., Mehde M., Grundmann A., Saile B., Scharf J. G. and Ramadori G. (2000). Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem. Cell Biol. 113, 443-453
24. Kweon Y. O., Goodman Z. D., Dienstag J. L., Schiff E. R., Brown N. A., Burchardt E., Schoohoven R., Brenner D. A. and Fried M. W. (2001). Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis Br. J. Hepatol. 35, 749-755.
25. Leung T. M., Tipoe G. L., Liong E. C., Lau T. Y. H., Fung M. L. and Nanji A. A. (2008). Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int. J. Exp. Pathol. 89, 241-250.
26. Li D. and Friedman S. L. (1999). Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J. Gastroenterol. Hepatol. 14, 618-633.
27. Losser M. R. and Payen D. (1996). Mechanisms of liver damage. Semin. Liver Dis. 16, 357-367.
28. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P. and Mallat A. (2005). Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 45, 605-628.
29. McCrudden R. and Iredale J. P. (2000). Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 15, 1159-1168.
30. Mittal M. K., Gupta T. K., Lee F. Y., Sieber C. C. and Groszmann R. J. (1994). Nitric oxide modulates hepatic vascular tone in normal rat liver. Am. J. Physiol. 267, G416-G422.
31. Moncada S. and Higgs A. (1993). The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2012.
32. Moncada S., Palmer R. M. and Higgs E. A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109-142.
33. Petermann H., Vogl S., Schulze E. and Dargel R. (1999). Chronic liver injury alters basal and stimulated nitric oxide production and 3H-thymidine incorporation in cultured sinusoidal endothelial cells from rats. J. Hepatol. 31, 284-292.
34. Ramadori G. and Saile B. (2004). Inflammation, damage repair, immune cells, and liver fibrosis: specific or nonspecific, this is the question. Gastroenterology 127, 997-1000.
35. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A. B., Sporn M. B. and Thorgeirsson S. S. (1995). Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 92, 2572-2576.
36. Schuppan D., Ruehl M., Somasundaram R. and Hahn E. G. (2001). Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 21, 351-372.
37. Wei C. L., Khoo H. E., Lee K. H. and Hon W. M. (2002). Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats. Nitric Oxide 7, 91-102.
38. Weber L. W., Boll M. and Stampfl A. (2003). Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33, 105-136.
39. 4-induced acute liver injury of mice. Free Radic. Biol. Med. 29, 870-880.